In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Zimmer Trabecular Metal hips: Patients implanted with Zimmer's highly porous Trabecular Metal monoblock hip replacement cups showed up to 41% mean bone density growth around some areas of their hip implants, compared to a 45% loss in density in some areas around titanium cups, over a mean follow-up of 7.7 years in a 17-patient study sponsored by Zimmer. The results are published in the May Journal of Arthroplasty. The study, led by researchers at the Mayo Clinic and the Indiana University Research Foundation, is the first to quantify bone remodeling around hip implants at an "intermediate term" of seven to nine years, according to the company

You may also be interested in...



Cardica Says PAS-Port Proximal Anastomosis System Is A Breakthrough

Cardica boasts it has achieved a major breakthrough in cardiac bypass surgery with its PAS-Port and C-Port fully automated anastomosis system

Tissue Valve Firms Target Younger Patients, Want Guidelines To Match

Tissue-based heart valve manufacturers are pushing to expand the treatment population for their products to include younger individuals

Aurobindo Upbeat On Outlook, Transfers Biologics Biz

After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.    

Topics

UsernamePublicRestriction

Register

LL1132035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel